Furthermore, measuring c-MYC mRNA levels (using RT-qPCR) and protein levels (using Western blotting) in relevant c-MYC-driven cancer cell lines (e.g., glioblastoma or Burkitt’s lymphoma lines) upon EGCG treatment would be essential to confirm whether the observed in vitro G4 binding translates into functional c-MYC repression in a cellular environment. This evidence concerns the gene MYC and glioblastoma.